Synthetic cell membranes invented at the Institute of Materials Research and Engineering (IMRE), a research institute of Singapores Agency for Science, Technology and Research (A*STAR), may improve the way we identify and develop drugs by speeding up and reducing the cost of the drug screening process. The technology earned a spot as one of the twelve finalists in the Asian Innovation Awards 2011 organized by the Wall Street Journal Asia.
They may look and act like natural human cell membranes but the synthetic cell membranes invented by A*STARs IMRE have more advantages. IMREs patented synthetic cell membranes can be made-to-order, are easier to maintain in a laboratory environment and do not require the lengthy preparation that comes with working on live cell membranes. The synthetic cell membranes mimic the natural functions of cell membranes, such as interacting with drug molecules and antibodies, which is crucial in the drug discovery process. The innovation also provides a more stable membrane model for a better understanding of the mechanisms of diseases that affect human cells.
A team of researchers led by IMREs Dr. Madhavan Nallani successfully used synthetic materials to mimic biological processes. We have harnessed natural cellular processes to fabricate a simple yet functional system using engineered materials to mimic the cell membrane and its proteins, said Dr. Nallani, the IMRE scientist who invented the synthetic cell membranes. These artificial cell membranes allow researchers to study interactions between membrane proteins, drugs and other compounds without the hassle of using living materials.
Cells communicate with each other through membrane proteins. The disruption of this communication mechanism causes diseases like cancer, diabetes and even Parkinsons disease. Understanding the workings of membrane proteins is very crucial in creating medicines to combat these diseases, explained Professor Eva Sinner, a visiting scientist at IMRE who works on biomaterials and is involved in the project.
Current methods of drug testing require living cells, which entail high capital and maintenance costs, as well as specialists to operate sophisticated equipment. IMREs patented synthetic cell membranes, which are essentially membrane proteins inserted into a stable polymer matrix outside a cellular environment, creates a platform for researchers to work on that both simple to use and easy to maintain.
This innovation is a classic example of how materials R&D can be applied to biomedical technologies, said Prof Andy Hor, Executive Director of IMRE. The success of this technology will be a great boost in helping create better drugs faster and more cost effectively.
Dr. Nallani is currently looking for partners to commercialise the technology. The invention has direct impact and application in fields like drug discovery, antibody and therapeutics development, and drug delivery, which are collectively worth some US$170 billion dollars.
Explore further: Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks